Thermo Fisher Scientific has announced a strategic data collaboration with HealthVerity, a prominent real-world data marketplace. This partnership will provide Thermo Fisher’s PPD clinical research business with extensive access to de-identified patient data. The initiative is designed to enhance data-driven clinical development and evidence generation for biopharmaceutical sponsors.
Expanding Access to Real-World Data
Under the agreement, the PPD business gains enterprise-level access to the HealthVerity taXOnomy® claims dataset. This comprehensive resource represents more than 270 million de-identified patient lives across the United States healthcare system. It will offer deep insights into disease prevalence, treatment patterns, and healthcare provider activity.
The collaboration also includes access to a marketplace of over 70 curated data sources. These diverse datasets encompass electronic medical records, laboratory results, and other specialized information. Streamlined access to this longitudinal and linked data will enable the delivery of more precise and efficient research strategies.
Enhancing Clinical Trial Efficiency
This infusion of high-quality data is set to significantly improve the efficiency of clinical trial processes. It will strengthen services across trial feasibility, optimization, and patient recruitment, leading to more precise site selection strategies. Consequently, biopharma clients can expect improved study startup timelines and more robust trial execution.
Krishna Cheriath, a vice president at Thermo Fisher Scientific, highlighted the collaboration's strategic value. He stated that integrating this high-quality, linked healthcare data with the company's AI-enabled analytics advances their capabilities significantly. This synergy allows for the generation of robust real-world evidence to support customers throughout the entire clinical and post-approval continuum.
Strengthening Evidence Generation and Outcomes Research
The partnership also extends benefits to post-approval research and health economics. It enhances the offerings of PPD CorEvitas Clinical Registries and PPD Evidera solutions. This will enable faster analytics and expanded registry-linked claims capabilities, which are crucial for health economics and outcomes research (HEOR).
Joseph Satili, chief commercial officer at HealthVerity, expressed pride in supporting Thermo Fisher's mission. He noted that enterprise access to robust real-world insights allows research teams to operate with greater speed and confidence. This improved efficiency impacts all stages of a study, from initial design to final evidence generation.
A Strategic Move in Digital Innovation
This collaboration is a key component of Thermo Fisher’s ongoing investment in digital innovation for clinical development. The company aims to foster smarter and more efficient research processes while maintaining rigorous privacy protections and data governance standards. The agreement provides increased flexibility to deliver differentiated value to its biopharma partners.
The strategic alliance between Thermo Fisher Scientific and HealthVerity marks a significant advancement in the use of real-world data. By integrating vast healthcare datasets with advanced analytics, the partnership is poised to accelerate clinical development. Ultimately, this data-driven approach aims to improve patient outcomes by bringing new therapies to market more efficiently.